ISCK03
CAS No. 945526-43-2
ISCK03( ISCK 03 | ISCK-03 )
Catalog No. M16771 CAS No. 945526-43-2
A specific c-Kit inhibitor that inhibits c-kit phosphorylation in vitro and SCF-induced c-kit phosphorylation in human melanoma cells.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
2MG | 30 | In Stock |
|
5MG | 47 | In Stock |
|
10MG | 77 | In Stock |
|
25MG | 164 | In Stock |
|
50MG | 281 | In Stock |
|
100MG | 478 | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameISCK03
-
NoteResearch use only, not for human use.
-
Brief DescriptionA specific c-Kit inhibitor that inhibits c-kit phosphorylation in vitro and SCF-induced c-kit phosphorylation in human melanoma cells.
-
DescriptionA specific c-Kit inhibitor that inhibits c-kit phosphorylation in vitro and SCF-induced c-kit phosphorylation in human melanoma cells; also inhibits p44/42 ERK mitogen-activated protein kinase (MAPK) phosphorylation, does not inhibit HGF-induced phosphorylation of p44/42 ERK proteins; induces the dose-dependent depigmentation of newly regrown hair, promotes the depigmentation of UV-induced hyperpigmented spots in vivo; orally acitve.
-
In VitroPretreatment of 501mel cells with ISCK03 inhibits SCF-induced c-kit phosphorylation dose dependently. ISCK03 also inhibits p44/42 ERK mitogen-activated protein kinase (MAPK) phosphorylation, which is known to be involved in SCF/c-kit downstream signaling. However ISCK03 does not inhibit hepatocyte growth factor (HGF)-induced phosphorylation of p44/42 ERK proteins. ISCK03, a tyrosine kinase inhibitor specific to KIT, prevents survival of CCDC26-KD cells under low-serum conditions. All treated cells exhibits sensitivity to ISCK03 in a dose-dependent manner. After ISCK03 treatment, the survival of KD cells is suppressed to the same level as that of non-KD cells. Conversely, ISCK03 treatment has limited effects on the growth of control K562 and KD clone 3–4 cells under high-serum concentration conditions.
-
In VivoOral administration of ISCK03 induces the dose-dependent depigmentation of newly regrown hair, and this is reversed with cessation of ISCK03 treatment. The topical application of ISCK03 promotes the depigmentation of UV-induced hyperpigmented spots. Fontana-Masson staining analysis shows epidermal melanin is diminished in spots treated with ISCK03.
-
SynonymsISCK 03 | ISCK-03
-
PathwayAngiogenesis
-
Targetc-Kit
-
Recptorc-Kit
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number945526-43-2
-
Formula Weight355.45394
-
Molecular FormulaC19H21N3O2S
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 38 mg/mL
-
SMILESO=S(N(C1=CC=C(C(C)(C)C)C=C1)C2=CC=C(N3C=CN=C3)C=C2)=O
-
Chemical NameBenzenesulfonamide, 4-(1,1-dimethylethyl)-N-[4-(1H-imidazol-1-yl)phenyl]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Na YJ, et al. Biochem Pharmacol. 2007 Sep 1;74(5):780-6.
2. Kamlah F, et al. Int J Radiat Oncol Biol Phys. 2011 Aug 1;80(5):1541-9.
3. Hirano T, et al. Mol Cancer. 2015 Apr 19;14:90.
molnova catalog
related products
-
CHMFL-KIT-031
CHMFL-KIT-031 is a highly selective KIT kinase primary V559D mutant inhibitor with IC50/Kd of 28/266 nM.
-
AZD2932
AZD2932 is a new series of quinazoline ether inhibitor which potently inhibits VEGFR-2 and PDGFR with IC50s of 4 nM/8 nM/ 7 nM for PDGFRβ/VEGFR-2/Flt-3.
-
CP-673451
CP-673451 is a selective inhibitor of PDGFRα/β with IC50 of 10 nM/1 nM.